LeMaitre Vascular, Inc.
NASDAQ:LMATMedical - Instruments & Supplies
+$1.60 today
- Market cap
- $1.73B
- Beta
- 0.52
- P/E (TTM)
- 34.3
- EPS (TTM)
- $2.74
- Dividend yield
- 0.96%
Volume 0.22M
Average 0.26M
LMAT Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
LeMaitre Vascular, Inc.NASDAQ: LMAT
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses grows, but more slowly than its trailing trend
Q1 FY2026 operating expenses of $30.62M rose 6.3% year over year, behind the +9.6% change in trailing-twelve-month operating expenses. Sequentially, it rose 11.9% from the prior quarter. Over 3 fiscal years it compounded at +12.3% a year.
Context
- Operating expenses amounted to 44.3% of revenue in FY2025, down 0.5 pp from a year earlier.
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +6.3% toward the trailing-twelve-month pace of +9.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 110.63M USD
- Year-over-year change
- +12.1%
- 4-year CAGR
- +14.2%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 110.63M | +12.1% |
| FY2024 | 2024-12-31 | 98.65M | +9.2% |
| FY2023 | 2023-12-31 | 90.34M | +15.7% |
| FY2022 | 2022-12-31 | 78.07M | +20.2% |
| FY2021 | 2021-12-31 | 64.96M | — |
Operating Expenses vs competitors
How LMAT compares with its peers on the latest reported figures
- LMAT's LTM Mar 2026 operating expenses of $112.45M is the lowest of the 8 companies compared; the peer median is $833.56M.
- Its year-over-year change of +9.6% is the 4th highest of 8, against a peer median of +8.3%.
- Operating expenses amounts to 43.9% of revenue for LMAT, versus a peer median of 50.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $18.25B | +17.2% | +4.6% | 48.6% | |
| LTM Jun 2026 | $10.43B | +19.7% | +18.8% | 49.7% | |
| LTM Jun 2026 | $1.31B | -4.4% | -5.7% | 50.4% | |
| LTM Jun 2026 | $833.56M | +20.5% | +12.5% | 55.4% | |
| LTM Sep 2026 | $578.71M | +7.5% | +8.6% | 35.9% | |
| LTM Mar 2026 | $253.12M | +8.3% | +7.5% | 55.2% | |
| LTM Feb 2026 | $193.06M | -4.7% | +0.6% | 61.5% | |
| LTM Mar 2026 | $112.45M | +9.6% | +12.3% | 43.9% | |
| Peer median (excluding LMAT) | $833.56M | +8.3% | +7.5% | 50.4% | |
Competitors are the stored peer set for LMAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 154.42M | 161.65M | 193.48M | 219.86M | 249.6M |
| Cost of Revenue | 53.04M | 56.76M | 66.44M | 68.96M | 71.06M |
| Gross Profit | 101.38M | 104.9M | 127.05M | 150.9M | 178.54M |
| Gross Margin | 65.7% | 64.9% | 65.7% | 68.6% | 71.5% |
| Research & Development | 11.8M | 13.29M | 16.97M | 15.65M | 14.14M |
| Selling, General & Admin | 53.16M | 61.67M | 72.89M | 83M | 96.49M |
| Operating Expenses | 64.96M | 78.07M | 90.34M | 98.65M | 110.63M |
| Depreciation & Amortization | 9.48M | 9.43M | 9.52M | 9.67M | 10.42M |
| EBITDA | 45.98M | 36.92M | 48.99M | 66.75M | 90.79M |
| EBITDA Margin | 29.8% | 22.8% | 25.3% | 30.4% | 36.4% |
| Operating Income | 36.43M | 26.83M | 36.71M | 52.26M | 67.91M |
| Operating Margin | 23.6% | 16.6% | 19.0% | 23.8% | 27.2% |
| Interest Income | 197K | 986K | 3.08M | 4.95M | 13.09M |
| Interest Expense | 2.22M | 0 | 0 | 205K | 5.18M |
| Other Income / Expenses | (2.14M) | 661K | 2.76M | 4.62M | 7.27M |
| Income Before Tax | 34.29M | 27.49M | 39.48M | 56.88M | 75.18M |
| Pre-Tax Margin | 22.2% | 17.0% | 20.4% | 25.9% | 30.1% |
| Income Tax Expense | 7.38M | 6.85M | 9.37M | 12.84M | 17.45M |
| Net Income | 26.91M | 20.64M | 30.11M | 44.04M | 57.73M |
| Net Margin | 17.4% | 12.8% | 15.6% | 20.0% | 23.1% |
| EPS (Basic) | 1.27 | 0.94 | 1.36 | 1.96 | 2.55 |
| EPS (Diluted) | 1.25 | 0.93 | 1.34 | 1.93 | 2.52 |
| Weighted Avg Shares | 21.16M | 21.98M | 22.22M | 22.45M | 22.64M |
| Weighted Avg Shares (Diluted) | 21.48M | 22.17M | 22.42M | 22.78M | 22.93M |
LeMaitre Vascular, Inc.
NASDAQ:LMAT
Intrinsic Alpha fair value
Locked
Current Price
$75.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.